Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects.
Benufutamab (GEN1029; HexaBody-DR5/DR5; 20 µg/mL; 24 hours) induces potent cytotoxicity in multiple myeloma (MM) cells[1].
Benufutamab (GEN1029; HexaBody-DR5/DR5; 0.5-2 mg/kg; i.p.; once a week; for 9 weeks) shows significant antitumor activity in PDX models for colorectal cancer[2].
References:
[1]. Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172.
[2]. Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19(10):2126-2138.